This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, a 10-year disease prevalence forecast, and as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Worldwide, Datamonitor Healthcare estimates that in 2021, there were approximately 30.4 million prevalent cases of eating disorders in females aged 10–19 years, including 3.2 million cases of anorexia nervosa, 8.3 million cases of bulimia nervosa, and 11.1 million cases of binge eating disorder.
• In this demographic group, Datamonitor Healthcare forecasts the number of prevalent cases of eating disorders to increase to 32.3 million by 2030.
• Edgemont’s Fluoxetine Tablets, Eli Lilly’s Prozac, and Takeda’s Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
• There are only four industry-sponsored drugs in active clinical development for eating disorders, with one drug in Phase I and three in Phase II.
• Therapies in active clinical development for eating disorders target hypocretin/orexin receptor, ghrelin receptor, and melanocortin receptors. These therapies are being tested as oral and subcutaneous formulations.
• The only high-impact upcoming event for drugs in the eating disorders space is topline Phase II trial results for ACT-539313. The overall likelihood of approval of a Phase I eating disorders asset is 8.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 5.8 years from Phase I to approval, compared to 9.7 years in the overall psychiatry space.
• All of the clinical trials for eating disorders have been in Phase III.
• The US leads in terms of the number of eating disorders clinical trials globally. Clinical trial activity in the eating disorders space consists entirely of completed trials. Johnson & Johnson has the highest number of completed clinical trials for eating disorders, with two trials.
• Johnson & Johnson leads industry sponsors with the highest number of Phase III clinical trials for eating disorders.